YY1: A Master Regulator at the Crossroads of Targeted Cancer Therapy - A Commentary

Our recent publication entitled “YY1 downregulation underlies therapeutic response to molecular targeted agents” represents a significant advancement in our understanding of the molecular mechanisms governing drug resistance in oncogene-addicted cancers [1]. This groundbreaking study unveils the transcription factor Yin Yang 1 (YY1) as a critical determinant in the evolutionary trajectory from drug-sensitive to drug-resistant cancer cells, offering new perspectives on precision oncology and therapeutic resistance mechanisms.

YY1, a member of the GLI-Krüppel zinc finger transcription factor family, has emerged as a multifaceted regulator in cancer biology [2,3]. The protein exhibits remarkable versatility, functioning as both a transcriptional activator and repressor depending on the cellular context [4]. This dual nature has positioned YY1 as a critical player in numerous hallmarks of cancer, including uncontrolled cell proliferation, evasion of apoptosis, metabolic reprogramming, and therapeutic resistance [2,5]. 

Recent evidence suggests that YY1 overexpression correlates with poor prognosis across multiple cancer types, making it an attractive therapeutic target [5,6]. However, the complexity of YY1's regulatory functions has presented significant challenges in developing effective targeting strategies [2].

• Mechanistic framework of drug tolerance 

Our work provides compelling evidence that YY1 serves as a convergent regulatory node during targeted therapy with kinase inhibitors. The study demonstrates that pharmacological perturbation of the RTK/MAPK pathway leads to YY1 downregulation, which subsequently resumes upon therapeutic escape. This finding establishes a direct mechanistic link between pathway inhibition and transcriptional reprogramming through YY1. We employed a comprehensive approach combining ATAC-seq and RNA-seq analyses to map chromatin accessibility dynamics throughout the drug-sensitive, drug-tolerant, and drug-resistant continuum. This methodology revealed that YY1 occupancy undergoes dramatic fluctuations that mirror the therapeutic response trajectory. 

• Cell cycle and autophagy regulation 

One of the most significant contributions of this study is the elucidation of YY1's role in governing cell cycle progression and autophagic programs. The research demonstrates that YY1 depletion leads to G2/M phase arrest while simultaneously disrupting autophagosome-lysosome fusion. This dual mechanism provides a molecular explanation for how YY1 downregulation enhances therapeutic efficacy while preventing the emergence of drug resistance. 

The autophagy findings are particularly relevant given the growing recognition of autophagy as a key mechanism of chemoresistance in cancer [7,8]. Cancer cells frequently upregulate autophagy as a survival mechanism during therapeutic stress, enabling them to maintain energy production and cellular viability [7,9]. The demonstration that YY1 controls autophagic flux offers new opportunities for combination therapies targeting both oncogenic signaling and stress response pathways [10].

• Universal resistance mechanisms 

The study extends beyond EGFR-mutant lung cancer to demonstrate YY1's role across diverse oncogene-addicted cancer models. This universality suggests that YY1-mediated resistance represents a fundamental mechanism that transcends specific driver mutations. Such findings align with emerging concepts of convergent resistance pathways that operate across different cancer types and therapeutic modalities [11,12]. The identification of common resistance mechanisms is crucial for developing more effective therapeutic strategies [13,14]. Current approaches to overcome resistance often focus on specific mutations or pathway alterations, but the YY1 pathway represents a more fundamental level of regulation that could be broadly applicable [15]. 

• Epigenetic regulation and therapeutic resistance 

The study's emphasis on chromatin accessibility dynamics highlights the critical role of epigenetic regulation in therapeutic resistance. Mounting evidence indicates that epigenetic changes, particularly histone modifications and chromatin remodeling, play essential roles in drug resistance mechanisms. The ability of cancer cells to rapidly reprogram their epigenetic landscape provides a mechanism for adaptive resistance that can occur independently of genetic mutations [16]. 

Recent advances in chromatin-targeted drug discovery have opened new opportunities for therapeutic intervention [17]. The identification of YY1 as a key regulator of chromatin accessibility during targeted therapy provides a specific target within this broader epigenetic framework [16,17].

• Biomarker development 

The clinical validation provided by this study, demonstrating YY1 fluctuations in patient samples, establishes the foundation for biomarker development [1]. The ability to monitor YY1 expression levels could provide valuable insights into therapeutic response and resistance development [1]. This application aligns with the broader movement toward precision oncology, where molecular biomarkers guide treatment decisions [18,19]. The development of YY1-based biomarkers could enable more personalized treatment approaches, allowing clinicians to anticipate resistance and adjust therapeutic strategies accordingly [18]. Such applications represent a crucial step toward more effective precision oncology implementations [19]. 

• Combination therapy strategies 

The study's findings suggest several promising combination therapy approaches. Targeting YY1 alongside conventional kinase inhibitors could potentially prevent the emergence of drug-tolerant persister cells [1]. Additionally, the dual role of YY1 in cell cycle control and autophagy regulation suggests opportunities for combining YY1 inhibition with cell cycle checkpoint inhibitors or autophagy modulators [9,20]. Recent studies have highlighted the potential of combining YY1 inhibition with immunotherapy approaches [6,21]. Given YY1's role in immune evasion and PD-L1 regulation, such combinations could enhance both targeted therapy efficacy and immune recognition [6,22].

• Therapeutic targeting of YY1 

Despite the promising therapeutic potential, targeting YY1 presents significant challenges [2,7]. As a transcription factor, YY1 lacks traditional druggable binding sites, requiring innovative approaches such as protein-protein interaction inhibitors or indirect targeting strategies [7]. Current efforts focus on small molecule inhibitors, RNA interference, and gene editing techniques, though clinical translation remains limited [7]. The development of specific YY1 inhibitors must also consider the protein's essential roles in normal cellular functions [3,4]. Achieving therapeutic selectivity while minimizing toxicity to normal tissues represents a major challenge in YY1-targeted therapy development [2]. 

• Understanding context-dependent functions 

The dual nature of YY1 as both tumor promoter and suppressor in different contexts requires careful consideration in therapeutic development [4]. Recent studies have shown that YY1 can function as a tumor suppressor in certain cancer types, highlighting the need for context-specific therapeutic approaches [4,6]. Future research should focus on identifying the molecular determinants that govern YY1's context-dependent functions [4]. Understanding these mechanisms will be crucial for developing effective and safe YY1-targeted therapies [2,7].

The work represents a paradigm shift in our understanding of targeted therapy resistance mechanisms. By identifying YY1 as a master regulator of the drug-sensitive to drug-resistant transition, this study provides new opportunities for therapeutic intervention and biomarker development. The convergent role of YY1 across diverse oncogene-addicted cancers suggests broad therapeutic applicability. Moving forward, the challenge lies in translating these mechanistic insights into effective clinical interventions [7]. The development of YY1-targeted therapies, in combination with existing approaches, holds promise for overcoming one of the most significant obstacles in precision oncology [2,20]. As we continue to unravel the complex regulatory networks governing therapeutic resistance, studies like this provide essential foundations for the next generation of cancer treatments [14,16].

1. Zhou S, Zang J, Cai MC, Ye K, Liu J, et al. (2024) YY1 downregulation underlies therapeutic response to molecular targeted agents. Cell Death Dis 15: 862.
2. Hosea R, Hillary S, Wu S, Kasim V (2023) Targeting Transcription Factor YY1 for Cancer Treatment: Current Strategies and Future Directions. Cancers (Basel) 15: 3506.
3. Gordon S, Akopyan G, Garban H, Bonavida B (2006) Transcription factor YY1: Structure, function, and therapeutic implications in cancer biology. Oncogene 25: 1125-1142.
4. Sarvagalla S, Kolapalli SP, Vallabhapurapu S (2019) The Two Sides of YY1 in Cancer: A Friend and a Foe. Front Oncol 9: 1230.
5. Shi J, Hao A, Zhang Q, Sui G (2015) The role of YY1 in oncogenesis and its potential as a drug target in cancer therapies. Curr Cancer Drug Targets 15: 145-157.
6. Li M, Wei J, Xue C, Zhou X, Chen S, et al. (2023) Dissecting the roles and clinical potential of YY1 in the tumor microenvironment. Front Oncol 13: 1122110.
7. Yang ZJ, Chee CE, Huang S, Sinicrope FA (2011) The role of autophagy in cancer: Therapeutic implications. Mol Cancer Ther 10: 1533-1541.
8. Sui X, Chen R, Wang Z, Huang Z, Kong N, et al. (2013) Autophagy and chemotherapy resistance: A promising therapeutic target for cancer treatment. Cell Death Dis 4: 838.
9. Hassan AMIA, Zhao Y, Chen X, He C (2024) Blockage of Autophagy for Cancer Therapy: A Comprehensive Review. Int J Mol Sci 25: 7459.
10. Gremke N, Polo P, Dort A, Schneikert J, Elmshäuser S, et al. (2020) mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability. Nat Commun 11: 4684.
11. Sabnis AJ, Bivona TG (2019) Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology. Trends Mol Med 25: 185-197.
12. Xiang Y, Liu X, Wang Y, Zheng D, Meng Q, et al. (2024) Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: Promising strategies to overcoming challenges. Front Immunol 15: 1366260.
13. Min HY, Lee HY (2022) Molecular targeted therapy for anticancer treatment. Exp Mol Med 54: 1670-1694.
14. Jones MF, Smith CC (2024) Mechanisms of Resistance to Targeted Therapies in AML. Annual Review of Cancer Biology 8: 81-96.
15. Stubbs NM, Roady TJ, Schwermann MP, Eteshola EO, MacDonald WJ, et al. (2025) Acquired resistance to molecularly targeted therapies for cancer. Cancer Drug Resist 8: 27.
16. Wang N, Ma T, Yu B (2023) Targeting epigenetic regulators to overcome drug resistance in cancers. Signal Transduct Target Ther 8: 69.
17. Mullard A (2024) Chromatin-targeted drug discovery at "a very special moment". Nat Rev Drug Discov 23: 490-491.
18. Pritchard D (2025) Understanding Cancer Biomarkers and the Delivery of Personalized Medicine. Cancer Care.
19. Subbiah V (2024) Creating a World Where Precision Oncology is a Reality for All. AACR, Philadelphia, USA.
20. Shapiro GI, Harper JW (1999) Anticancer drug targets: Cell cycle and checkpoint control. J Clin Invest 104: 1645-1653.
21. Navasardyan I, Zaravinos A, Bonavida B (2024) Therapeutic Implications of Targeting YY1 in Glioblastoma. Cancers (Basel) 16: 2074.
22. Kwiatkowska D, Mazur E, Reich A (2022) YY1 Is a Key YY1 Is a Key Player in Melanoma Immunotherapy/Targeted Treatment Resistance. Front Oncol 12: 856963.